Plasma YKL-40 in relation to the degree of coronary artery disease in patients with stable ischemic heart disease

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 71, Issue 5, 2011, Pages 439-447

  Mathiasen, Anders B ^a   Harutyunyan, Marina J ^a   Jrgensen, Erik ^a   Helqvist, Steffen ^a   Ripa, Rasmus ^d   Gtze, Jens P ^b   Johansen, Julia S ^c   Kastrup, Jens ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b Rigshospitalet   (Denmark)

^c GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^d NONE

Author keywords

Biomarker; Coronary artery disease; HsCRP; Inflammation; Ischemic heart disease; YKL 40

Indexed keywords

C REACTIVE PROTEIN; CHITINASE; CHOLESTEROL; CREATININE; GLYCOPROTEIN; HIGH SENSITIVITY C REACTIVE PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; UNCLASSIFIED DRUG; YKL 40;

ADULT; AGE; ANGIOCARDIOGRAPHY; ARTICLE; CHOLESTEROL BLOOD LEVEL; COMPARATIVE STUDY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; CREATININE BLOOD LEVEL; DISEASE SEVERITY; FEMALE; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PATHOPHYSIOLOGY; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; PROGNOSIS; STABLE ANGINA PECTORIS;

ADIPOKINES; AGED; ANALYSIS OF VARIANCE; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; CORONARY STENOSIS; FEMALE; HUMANS; LECTINS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; REGRESSION ANALYSIS;

ANGINA;

EID: 80051762448     PISSN: 00365513     EISSN: 15027686     Source Type: Journal    
DOI: 10.3109/00365513.2011.586470     Document Type: Article

References (54)

1. Jensen LJ, Pedersen S, Bjerre M, Mogelvang R, Jensen JS, Flyvbjerg A. Plasma calprotectin predicts mortality in patients with ST segment elevation myocardial infarction treated with primary percutaneous coronary intervention. J Interv Cardiol 2010;23:123-9.
2. Manhenke C, Orn S, Squire I, Radauceanu A, Alla F, Zannad F, Dickstein K. The prognostic value of circulating markers of collagen turnover after acute myocardial infarction. Int J Cardiol 2010;19:19.
3. Mathiasen AB, Henningsen KM, Harutyunyan MJ, Mygind ND, Kastrup J. YKL-40: a new biomarker in cardiovascular disease? Biomark Med 2010;4:591-600.
4. Kastrup J. Can YKL-40 be a new inflammatory biomarker in cardiovascular disease? Immunobiology 2011 Apr 30. [Epub ahead of print].
5. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005;352:1685-95.
6. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999;340:115-26.
7. Insull W, Jr. The pathology of atherosclerosis: plaque development and plaque responses to medical treatment. Am J Med 2009;122:S3-S14.
8. Bussink AP, Speijer D, Aerts JM, Boot RG. Evolution of mammalian chitinase(-like) members of family 18 glycosyl hydrolases. Genetics 2007;177:959-70. (Pubitemid 350005647)
9. Boot RG, van Achterberg TA, van Aken BE, Renkema GH, Jacobs MJ, Aerts JM, de Vries CJ. Strong induction of members of the chitinase family of proteins in atherosclerosis: chitotriosidase and human cartilage gp-39 expressed in lesion macrophages. Arterioscler Thromb Vasc Biol 1999;19: 687-94. (Pubitemid 29135172)
10. Malinda KM, Ponce L, Kleinman HK, Shackelton LM, Millis AJ. Gp38k, a protein synthesized by vascular smooth muscle cells, stimulates directional migration of human umbilical vein endothelial cells. Exp Cell Res 1999;250:168-73. (Pubitemid 29391580)
11. Nishikawa KC, Millis AJ. gp38k (CHI3L1) is a novel adhesion and migration factor for vascular cells. Exp Cell Res 2003;287:79-87. (Pubitemid 36683203)
12. Shackelton LM, Mann DM, Millis AJ. Identification of a 38-kDa heparin-binding glycoprotein (gp38k) in differentiating vascular smooth muscle cells as a member of a group of proteins associated with tissue remodeling. J Biol Chem 1995;270:13076-83.
13. Hedegaard A, Sejersten RR, Johansen JS, Jorgensen E, Kastrup J. Plasma YKL-40 and recovery of left ventricular function after acute myocardial infarction. Scand J Clin Lab Invest 2010;70:80-6.
14. Kastrup J, Johansen JS, Winkel P, Hansen JF, Hildebrandt P, Jensen GB, Jespersen CM, Kjoller E, Kolmos HJ, Lind I, Nielsen H, Gluud C. High serum YKL-40 concentration is associated with cardiovascular and all-cause mortality in patients with stable coronary artery disease. Eur Heart J 2009;30:1066-72.
15. Kucur M, Isman FK, Karadag B, Vural VA, Tavsanoglu S. Serum YKL-40 levels in patients with coronary artery disease. Coron Artery Dis 2007;18:391-6. (Pubitemid 47186840)
16. Nojgaard C, Host NB, Christensen IJ, Poulsen SH, Egstrup K, Price PA, Johansen JS. Serum levels of YKL-40 increases in patients with acute myocardial infarction. Coron Artery Dis 2008;19:257-63.
17. Wang Y, Ripa RS, Johansen JS, Gabrielsen A, Steinbruchel DA, Friis T, Bindslev L, Haack-Sorensen M, Jorgensen E, Kastrup J. YKL-40 a new biomarker in patients with acute coronary syndrome or stable coronary artery disease. Scand Cardio-vasc J 2008;42:295-302.
18. Rathcke CN, Raymond I, Kistorp C, Hildebrandt P, Faber J, Vestergaard H. Low grade inflammation as measured by levels of YKL-40: Association with an increased overall and cardiovascular mortality rate in an elderly population. Int J Cardiol 2010;143:35-42.
19. Kronborg G, Ostergaard C, Weis N, Nielsen H, Obel N, Pedersen SS, Price PA, Johansen JS. Serum level of YKL-40 is elevated in patients with Streptococcus pneumoniae bac-teremia and is associated with the outcome of the disease. Scand J Infect Dis 2002;34:323-6. (Pubitemid 34746248)
20. Volck B, Johansen JS, Stoltenberg M, Garbarsch C, Price PA, Ostergaard M, Ostergaard K, Lovgreen-Nielsen P, Sonne-Holm S, Lorenzen I. Studies on YKL-40 in knee joints of patients with rheumatoid arthritis and osteoarthritis. Involvement of YKL-40 in the joint pathology. Osteoarthritis Cartilage 2001;9:203-14. (Pubitemid 32390204)
21. Vind I, Johansen JS, Price PA, Munkholm P. Serum YKL-40, a potential new marker of disease activity in patients with inflammatory bowel disease. Scand J Gastroenterol 2003;38: 599-605. (Pubitemid 36724038)
22. Nielsen AR, Erikstrup C, Johansen JS, Fischer CP, Plom-gaard P, Krogh-Madsen R, Taudorf S, Lindegaard B, Ped-ersen BK. Plasma YKL-40: a BMI-independent marker of type 2 diabetes. Diabetes 2008;57:3078-82.
23. Rathcke CN, Johansen JS, Vestergaard H. YKL-40, a bio-marker of inflammation, is elevated in patients with type 2 diabetes and is related to insulin resistance. Inflamm Res 2006;55:53-9.
24. Rathcke CN, Persson F, Tarnow L, Rossing P, Vestergaard H. YKL-40, a marker of inflammation and endothelial dysfunction, is elevated in patients with type 1 diabetes and increases with levels of albuminuria. Diabetes Care 2009; 32:323-8.
25. Chupp GL, Lee CG, Jarjour N, Shim YM, Holm CT, He S, Dziura JD, Reed J, Coyle AJ, Kiener P, Cullen M, Grand-saigne M, Dombret MC, Aubier M, Pretolani M, Elias JA. A chitinase-like protein in the lung and circulation of patients with severe asthma. N Engl J Med 2007;357:2016-27. (Pubitemid 350106709)
26. Letuve S, Kozhich A, Arouche N, Grandsaigne M, Reed J, Dombret MC, Kiener PA, Aubier M, Coyle AJ, Pretolani M. YKL-40 is elevated in patients with chronic obstructive pulmonary disease and activates alveolar macrophages. J Immunol 2008;181:5167-73.
27. Johansen JS. Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodelling, fibroses and cancer. Dan Med Bull 2006;53:172-209. (Pubitemid 43772025)
28. Johansen JS, Jensen BV, Roslind A, Nielsen D, Price PA. Serum YKL-40, a new prognostic biomarker in cancer patients? Cancer Epidemiol Biomarkers Prev 2006;15:194-202. (Pubitemid 43342164)
29. Johansen JS, Hoyer PE, Larsen LA, Price PA, Mollgard K. YKL-40 protein expression in the early developing human musculoskeletal system. J Histochem Cytochem 2007;55: 1213-28. (Pubitemid 350156079)
30. Saidi A, Javerzat S, Bellahcene A, De VJ, Bello L, Castronovo V, Deprez M, Loiseau H, Bikfalvi A, Hagedorn M. Experimental anti-angiogenesis causes upregulation of genes associated with poor survival in glioblastoma. Int J Cancer 2008;122:2187-98. (Pubitemid 351542321)
31. Shao R, Hamel K, Petersen L, Cao QJ, Arenas RB, Bigelow C, Bentley B, Ya n W. YKL-40, a secreted glycoprotein, promotes tumor angiogenesis. Oncogene 2009;28:4456-68.
32. Lee CG, Hartl D, Lee GR, Koller B, Matsuura H, Da Silva CA, Sohn MH, Cohn L, Homer RJ, Kozhich AA, Humbles A, Kearley J, Coyle A, Chupp G, Reed J, Flavell RA, Elias JA. Role of breast regression protein 39 (BRP-39)/chitinase 3-like-1 in Th2 and IL-13-induced tissue responses and apoptosis. J Exp Med 2009;206:1149-66.
33. Mizoguchi E, Mizoguchi A. Is the sugar always sweet in intestinal inflammation? Immunol Res 2007;37:47-60. (Pubitemid 46742283)
34. Ling H, Recklies AD. The chitinase 3-like protein human cartilage glycoprotein 39 inhibits cellular responses to the inflammatory cytokines interleukin-1 and tumour necrosis factor-alpha. Biochem J 2004;380:651-9. (Pubitemid 38850506)
35. Recklies AD, White C, Ling H. The chitinase 3-like protein human cartilage glycoprotein 39 (HC-gp39) stimulates proliferation of human connective-tissue cells and activates both extracellular signal-regulated kinase-and protein kinase B-mediated signalling pathways. Biochem J 2002;365: 119-26. (Pubitemid 34756146)
36. Arima H, Kubo M, Yonemoto K, Doi Y, Ninomiya T, Tanizaki Y, Hata J, Matsumura K, Iida M, Kiyohara Y. High-sensitivity C-reactive protein and coronary heart disease in a general population of Japanese: the Hisayama study. Arterioscler Thromb Vasc Biol 2008;28:1385-91.
37. Koenig W, Lowel H, Baumert J, Meisinger C. C-reactive protein modulates risk prediction based on the Framingham Score: implications for future risk assessment: results from a large cohort study in southern Germany. Circulation 2004;109:1349-53. (Pubitemid 38387819)
38. Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 2001;285:2481-5. (Pubitemid 32433842)
39. Albert CM, Ma J, Rifai N, Stampfer MJ, Ridker PM. Prospective study of C-reactive protein, homocysteine, and plasma lipid levels as predictors of sudden cardiac death. Circulation 2002;105:2595-9. (Pubitemid 34596034)
40. Koenig W, Khuseyinova N, Baumert J, Meisinger C. Prospective study of high-sensitivity C-reactive protein as a determinant of mortality: results from the MONICA/KORA Augsburg Cohort Study, 1984-1998. Clin Chem 2008;54:335-42. (Pubitemid 351302620)
41. Mueller C, Buettner HJ, Hodgson JM, Marsch S, Perruchoud AP, Roskamm H, Neumann FJ. Inflammation and long-term mortality after non-ST elevation acute coronary syndrome treated with a very early invasive strategy in 1042 consecutive patients. Circulation 2002;105:1412-5. (Pubitemid 34263269)
42. Mueller C, Laule-Kilian K, Christ A, Brunner-La Rocca HP, Perruchoud A P. Inflammation and long-term mortality in acute congestive heart failure. Am Heart J 2006;151:845-50.
43. Kushner I, Rzewnicki D, Samols D. What does minor elevation of C-reactive protein signify? Am J Med 2006;119:166. e17-28.
44. Johansen JS, Lottenburger T, Nielsen HJ, Jensen JE, Svendsen MN, Kollerup G, Christensen IJ. Diurnal, weekly, and long-time variation in serum concentrations of YKL-40 in healthy subjects. Cancer Epidemiol Biomarkers Prev 2008;17:2603-8.
45. Hogdall EV, Johansen JS, Kjaer SK, Price PA, Blaakjaer J, Hogdall CK. Stability of YKL-40 concentration in blood samples. Scand J Clin Lab Invest 2000;60:247-51.
46. Rathcke CN, Kj ø ller E, Fogh-Andersen N, Zerahn B, Vester-gaard H. NT-proBNP and circulating inflammation markers in prediction of a normal myocardial scintigraphy in patients with symptoms of coronary artery disease. PLoS ONE 2010;5:e14196.
47. Mygind ND, Harutyunyan MJ, Mathiasen AB, Ripa RS, Thune JJ, Gøtze JP, Johansen JS, Kastrup J. The influence of statin treatment on the inflammatory biomarkers YKL-40 and HsCRP in patients with stable coronary artery disease. Inflamm Res 2010;60:281-7.
48. Mezzetti A. Pharmacological modulation of plaque instability. Lupus 2005;14:769-72. (Pubitemid 41413309)
49. Rathcke CN, Holmkvist J, Jorgensen T, Borch-Johnsen K, Hansen T, Pedersen OB, Vestergaard H. Variation in CHI3LI in relation to type 2 diabetes and related quantitative traits. PLoS One 2009;4:e5469.
50. Rathcke CN, Vestergaard H. YKL-40-an emerging bio-marker in cardiovascular disease and diabetes. Cardiovasc Diabetol 2009;8:61.
51. Luc G, Bard JM, Juhan-Vague I, Ferrieres J, Evans A, Amouyel P, Arveiler D, Fruchart JC, Ducimetiere P. C-reac-tive protein, interleukin-6, and fibrinogen as predictors of coronary heart disease: the PRIME Study. Arterioscler Thromb Vasc Biol 2003;23:1255-61. (Pubitemid 36871282)
52. Bonnet J, McPherson R, Tedgui A, Simoneau D, Nozza A, Martineau P, Davignon J. Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: results of the CAP (Comparative Atorvastatin Pleiotropic effects) study. Clin Ther 2008;30:2298-313.
53. Hempen M, Kopp HP, Elhenicky M, Hobaus C, Brix JM, Koppensteiner R, Schernthaner G, Schernthaner GH. YKL-40 is elevated in morbidly obese patients and declines after weight loss. Obes Surg 2009;19:1557-63.
54. Henningsen KM, Therkelsen SK, Johansen JS, Bruunsgaard H, Svendsen JH. Plasma YKL-40, a new biomarker for atrial fibrillation? Europace 2009;11:1032-6.